GlassScriptPhysician profile
Kelly Ann Shine
NPI 1477522472
$892.64
in general payments reported to CMS, 2019-2025
15 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.44 · 2021: $137 · 2022: $252 · 2023: $205 · 2024: $99.00 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $118.22 | 2021-2025 | |
| Janssen Biotech, INC. | $114.45 | 2022-2024 | Stelara |
| Braintree Laboratories, INC. | $110.79 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.71 | 2023-2025 | Entyvio |
| Tela Bio, INC. | $87.80 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.88 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $61.92 | 2023-2025 | Voquezna |
| Smith+Nephew, INC. | $38.95 | 2024 | Grafix Pl |
| Ferring Pharmaceuticals INC. | $35.03 | 2022 | |
| Aimmune Therapeutics, INC. | $24.47 | 2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $23.92 | 2022 | |
| Heron Therapeutics, INC. | $22.96 | 2023 | Zynrelef |
| Boston Scientific Corporation | $21.07 | 2022 | |
| Merck Sharp & Dohme LLC | $20.58 | 2022 | |
| Genzyme Corporation | $18.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Shine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.